Page 856 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

834 Index

PDGFR. see Platelet-derived growth factor Pesticide, 15 Pituitary tumors, 565
observational studies for, 87t–91t, 92
receptor Pharmaceutics, 190 Placental alkaline phosphatase (PLAP), 628
Planning target volume (PTV), 215–216
PDH. see Pituitary-dependent
VetBooks.ir Pemphigus vulgaris Pharmacodynamics, for cytotoxic PLAP. see Placental alkaline phosphatase
hypercortisolism
chemotherapy, 189–190
Plasma aldosterone, in feline adrenocortical
characteristics of, 106 Pharmacokinetics tumors, 573
lymphoma and, 99b cancer therapies and, 188–189 Plasma cell tumor
Penile tumor time plot versus C MAX and AUC, 189f cell characteristics in, 142
canine, 636–637 Pharmacologic appetite stimulation, 304 immunohistochemical markers/panels for,
feline, 637 Pharmacologic therapy, pain management 72t–73t
Percent necrosis, molecular mechanism for, 69t and, 290–297 Plasmacytoma
Perianal adenocarcinoma, 19, 468–470 Pharyngeal tumor, 287t cell characteristics in, 142
Perianal adenoma, 468–470 Phase 0 trial, 343 fine-needle aspiration of, 142f
androgens and, 19 Phase I trial in spinal cord, 666t
diagnostic techniques and workup for, 469 dose selection for, 341 Plasmid DNA, 239–240
fine-needle aspiration of, 134f escalation strategies in, 341–342, 341t Platelet aggregation, cancer progression and,
history and clinical signs of, 469 goals of, 340–341, 341t 104
incidence and risk factors for, 468–469 Phase II trial Platelet-derived growth factor receptor
pathology and natural behavior of, 469 endpoints of activity/efficacy, 342–343 (PDGFR), 6
prognosis for, 470 goals of, 341t, 342 expression of, 258
treatment for, 469–470 Phase III trial, 343–344 Platelet-derived growth factor-β (PDGF-β),
Perianal gland tumor, 134 goals of, 341t role of, 6
Perianal tumors, 468 Phase IV trial, 344–346 Platinum clearance, 189f
Periarticular tumors, 553 Phenoxy acid-containing herbicide, 92 Pleomorphic cell, 130–131
Pericyte, 50 Pheochromocytomas, 573 Pleomorphic sarcoma, 405t, 406
Perinuclear vacuolation, 133 Philadelphia (Ph) chromosome, 11–12, 42 Pleomorphism, 133
Periodic acid-Schiff (PAS) stain, 71t CML, ALL, AML and, 148 PLG. see Pulmonary lymphomatoid
for carbohydrates, 129 Phosphatidyl inositol-3 kinase (PI3K), granulomatosis
Perioperative chemotherapy, 170 258–259 Plutonium-induced OSA, 524–525
Peripheral blood mononuclear cell (PBMC), signal transduction, 260f PMR. see Proportional morbidity ratio
237 Phosphorylation, 36–37 PNS. see Paraneoplastic syndrome
Peripheral mastocytosis, 389 Photobiomodulation, 336 PNST. see Peripheral nerve sheath tumor
Peripheral nerve, tumors of, 406–407 Photodynamic therapy, 169–170 Point mutation, 40f, 42–43
Peripheral nerve sheath tumor (PNST), 405t, for nasal planum, cancer of, 494 cause of, 259–260
406–407, 666t or Bowen’s disease, 357 Poly adenosine diphosphate ribose
cell characteristics in, 138 Photon, 210–211 glycohydrolase (PARG), 272
classification of, 669 Phrenicoabdominal venotomy, for adrenal inhibition, 272
clinical signs of, 669–670 tumors, 574 Poly adenosine diphosphate ribose polymerase
comparative pathology of, 669, 669f Physical carcinogenesis (PARP), 272
diagnosis of, 670 asbestos, 17 inhibition, 272
epidemiology of, 669 magnetic fields and, 16 Polymerase chain reaction (PCR), 74
history of, 669–670 radiation, 16 c-kit mutation detection by, 149f
pathophysiology of, 669–670 sunlight, 16 genetic insertions/deletions and, 148
prognosis for, 670 trauma/chronic inflammation, 16 papillomaviruses and, 353
treatment of, 670 Physical examination, for intestinal tumors, sequencing in, 148
Peripheral nerve tumors, 669 463 single-base mutations, 148
Peripheral neuropathy, 99b, 106 PI3K/Akt signaling pathway, 153 Polypoid cystitis, 648f
Peripheral nodal lymphoma, in cats, 723–724, Piedmont Canine Cancer Registry, 83t Polysulphated glycosaminoglycan, 293t–294t
723f–724f Pilomatricoma, 359 Poorly differentiated epithelial tumor, 132
mediastinal lymphoma, 724 PIN. see Prostatic intraepithelial neoplasia Population-based cancer registry, 83
Peripheral noradrenergic receptor, 296 Piroxicam Population pharmacokinetic study, 198
Peripheral odontogenic fibroma, 435 dose and effects of, 293t–294t Population studying, 94
prognosis of, 444–445 efficacy of, 264 Positron-emission tomography (PET), glucose
Peripheral parenteral nutrition (PPN), 305 for oral melanoma, 374–375 uptake and, 9
Peripheral T-cell lymphoma-not otherwise for urinary bladder tumors, 649t–650t Positron-emission tomography/computed
specified (PTCL-NOS), 700t Pituitary corticotroph tumors, 565–569 tomography (PET/CT), 118–121
Perivascular wall tumor, 405t Pituitary-dependent hyperadrenocorticism, Postregistration trials, 344–346
cell characteristics in, 141 feline, 568–569, 569f Posttreatment biopsy, 158
fine-needle aspiration of, 139f Pituitary-dependent hypercortisolism (PDH), Power, in clinical trial, 343–344
Personalized medicine, 330, 347–348 565 Poxvirus, use of, 240
approaches to, 347 canine, treatment of, 567–568 PPN. see Partial parenteral nutrition
field of, 347 Pituitary somatotroph tumors, 569–571, 570f Precursor lymphoma, 700t